A prospective survey of the use of dexamethasone on a palliative care unit

被引:94
作者
Hardy, JR [1 ]
Rees, E [1 ]
Ling, J [1 ]
Burman, R [1 ]
Feuer, D [1 ]
Broadley, K [1 ]
Stone, P [1 ]
机构
[1] Royal Marsden NHS Trust, Dept Palliat Med, Sutton SM2 5PT, Surrey, England
关键词
corticosteroids; palliative care; prescription guidelines;
D O I
10.1191/026921601673324846
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
One hundred and six consecutive patients started on glucocorticosteroids (steroids) according to a defined prescription policy were surveyed each week to document the indications for use, any beneficial effect, any toxicity incurred and the reason for stopping. All patients had advanced malignant disease and survived for a median of 40.5 days (range 1-398 + days) from the start of steroid treatment. Fifty-seven per cent of patients completed three or more assessments. The most common specific indications for starting steroids were spinal cord compression, cerebral metastases, lymphangitis carcinomatosa and intestinal obstruction. The most common non-specific indications were anorexia, nausea, low mood, pain and vomiting. The median duration of steroid use was 21.5 days (range 1-89 days). The most common reason for the discontinuation of steroids was death or deteriorating condition. Symptom scores improved at some stage for the majority of patients started on steroids for anorexia, nausea, pain, low mood, vomiting and weakness but not in patients complaining of dyspnoea or poor mobility. The most common side-effects that were most probably attributable to steroid therapy were oral candidosis and proximal myopathy. The benefits of steroids when used according to defined guidelines were thought to outweigh toxicity.
引用
收藏
页码:3 / 8
页数:6
相关论文
共 9 条
[1]   Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury - A meta-analysis of randomized controlled clinical trials [J].
Koch, M ;
Dezi, A ;
Ferrario, F ;
Capurso, L .
ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (20) :2321-2332
[2]  
MINTON MJ, 1981, CANCER, V48, P883, DOI 10.1002/1097-0142(19810815)48:4<883::AID-CNCR2820480404>3.0.CO
[3]  
2-V
[4]   STEROIDS IN ADVANCED CANCER - SURVEY OF CURRENT PRACTICE [J].
NEEDHAM, PR ;
DALEY, AG ;
LENNARD, RF .
BRITISH MEDICAL JOURNAL, 1992, 305 (6860) :999-999
[5]   CORTICOSTEROID USE AND PEPTIC-ULCER DISEASE - ROLE OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS [J].
PIPER, JM ;
RAY, WA ;
DAUGHERTY, JR ;
GRIFFIN, MR .
ANNALS OF INTERNAL MEDICINE, 1991, 114 (09) :735-740
[6]   Fatigue in advanced cancer: a prospective controlled cross-sectional study [J].
Stone, P ;
Hardy, J ;
Broadley, K ;
Tookman, AJ ;
Kurowska, A ;
A'Hern, R .
BRITISH JOURNAL OF CANCER, 1999, 79 (9-10) :1479-1486
[7]   TREATMENT OF METASTATIC PROSTATIC-CANCER WITH LOW-DOSE PREDNISONE - EVALUATION OF PAIN AND QUALITY OF LIFE AS PRAGMATIC INDEXES OF RESPONSE [J].
TANNOCK, I ;
GOSPODAROWICZ, M ;
MEAKIN, W ;
PANZARELLA, T ;
STEWART, L ;
RIDER, W .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (05) :590-597
[8]   CORTICOSTEROIDS IN ADVANCED CANCER [J].
TWYCROSS, R .
BRITISH MEDICAL JOURNAL, 1992, 305 (6860) :969-970